Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
about
A Perspective of Immunotherapy for Prostate CancerNew drugs in prostate cancerPrioritization schema for immunotherapy clinical trials in glioblastoma.Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.Immunotherapy of Prostate Cancer: Facts and Hopes.Current achievements and future perspectives of metronomic chemotherapy.Drug discovery in advanced prostate cancer: translating biology into therapy.Therapeutic vaccines for prostate cancer: recent advances and future directions.Immunotherapy for prostate cancer: False promises or true hope?Immune modulation by dendritic-cell-based cancer vaccines.PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.Immuno-oncology combinations: raising the tail of the survival curve.Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death.Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer.The evolution of chemotherapy for the treatment of prostate cancer.Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.Promising immunotherapy for prostate cancer.Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.Trial watch: Dendritic cell-based anticancer immunotherapy.Perspectives on the clinical development of immunotherapy in prostate cancer.A novel prostate cancer immunotherapy using prostate-specific antigen peptides and skin test reagent as an adjuvantDendritic cells pulsed with generated tumor cell lysate from Phyllanthus amarus Schum. & Thonn. induces anti-tumor immune response
P2860
Q26741277-2927E6C5-AA8B-48B6-A3F7-F7F0FAA25EA4Q26745948-86FB8FC2-C3E7-4F1F-81FF-43531B485E19Q37078999-937F578E-0413-44BB-93C4-38F8A5362EA0Q37564665-BBFB64CF-C735-4873-B414-2EF22849664FQ37688558-992527E5-6018-48E5-AFC2-EC3EACAA0CBDQ37741161-EC42D2BA-0285-454D-BAAC-9DBA2130E765Q38366904-51E6DF8E-BFFE-4BD0-BC34-FC0337C20E12Q38664882-A726B84F-40F7-45D4-BA42-EC317D1F48D2Q38788234-36A7C67D-DA9C-4BAA-9FF6-BE15D44F3DE4Q38839110-B8113632-327D-47DD-81C5-9341A0BC743AQ38906558-2AEF60E9-4B2D-4954-BF75-52DB0BD8F8E6Q38959645-DC6E90DF-78D4-4211-8899-E3C7D8A9080EQ39147683-023E1C1C-2810-4A1D-AB16-D9F1952069DDQ41057575-30B2909D-09C1-4ABA-81F1-8BA55CAD9B4CQ42421273-347E8BCA-1432-4C40-A5D7-2F917019CB37Q42925679-D716B2E8-4907-487D-9391-E3FFBD1EB013Q45160319-44CA0A88-6C33-4905-AE40-4FC2F2FD9F57Q45896413-0DB94357-1975-4A0E-93E2-C9AEFFA4064DQ45943517-D6603F3B-BA98-41CF-9B46-209D6240D109Q47105622-836EFB02-6E99-467C-AB64-C28C32CAADB8Q47361686-BB89B7C8-B112-488F-AD3F-9110C25DED8DQ47566793-445459D1-0EB1-42CC-852A-3CA3B6F09FD7Q48135793-51C7054C-EC32-4280-84CF-E1659A98C714Q49835554-F5827DB2-CA2C-4ACE-A577-6668E030782FQ50947703-DC5AB096-06BF-44BD-886C-44DAF23C04F9Q53109846-0FD8DFC7-95A2-4200-A176-2D6FE6D91B00Q55029444-499729CA-56CC-4AC0-8F15-AC666EBFE1B4Q58732160-6CFFB750-DEDC-4F9A-A119-8047A52F3524Q58799435-AB3A8A23-D65C-454A-A7BA-28C5C89FE7A9
P2860
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@ast
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@en
type
label
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@ast
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@en
prefLabel
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@ast
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@en
P2093
P2860
P921
P356
P1433
P1476
Phase I/II clinical trial of d ...... ion-resistant prostate cancer.
@en
P2093
Daniela Rozkova
Etienne Becht
Hana Hromadkova
Jana Kayserova
Jirina Bartunkova
Jitka Fucikova
Katerina Kubackova
Katerina Vavrova
Klara Sochorova
Ladislav Jarolim
P2860
P304
18192-18205
P356
10.18632/ONCOTARGET.4145
P407
P577
2015-05-29T00:00:00Z